Vikas Kumar

Vikas Kumar

Auto-generated profile, based on publicly available information

Vikas Kumar

Department of Biochemistry, All India Institute of Medical Sciences, New Delhi, India

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 April 2022 in Bioscience Reports
Verified
Journal Article
Open access
PDF file
AKANURAG KUMAR
ANURAG KUMAR
VKVikas Kumar
Vikas Kumar
MAMohit Arora
Mohit Arora
MKManish Kumar
Manish Kumar
PAPrajwal Ammalli
Prajwal Ammalli
SCShyam Chauhan
Shyam Chauhan
Prothymosin-α (PTMA), a nuclear protein, is strikingly associated with unfavorable clinical outcomes in many cancers. However, no information about its clinical relevance in glioma was available. Therefore in the present study, we evaluated the prognostic utility of this protein in a cohort of 81 glioma patients. The PTMA expression was assessed by immunohistochemical analysis, quantitative PCR, and Western blotting. Furthermore, the association of PTMA with clinicopathological features and molecular alterations were assessed in the patient cohort and validated in multiomics datasets, The Cancer Genome Atlas (TCGA; n=667) and Chinese Glioma Genome Atlas (CGGA; n=1013). We observed an increase in PTMA expression with increasing histological grades of this malignancy. PTMA immunostaining also displayed a strong positive association with the MIB-1 index. Univariate analysis revealed a superior prognostic value of PTMA to predict overall survival (OS) as compared with the routinely used markers (p53, isocitrate dehydrogenase (IDH) 1 (IDH1), α-thalassemia/intellectual disability syndrome X-linked (ATRX), and Ki-67). Interestingly, in Cox regression analysis it emerged as an independent predictor of OS (hazard ratio (HR) = 13.71, 95% CI = 5.96–31.52, P<0.0001). Thus, our results demonstrate the potential prognostic utility of PTMA in glioma which may prove useful in the management of this deadly malignancy.

5 November 2019 in International Journal of Diabetes in Developing Countries
Verified
Journal Article
Closed access
PDF file
RCRajeev Chawla
Rajeev Chawla
BMB. M. Makkar
B. M. Makkar
SASudeepta Aggarwal
Sudeepta Aggarwal
SBSarita Bajaj
Sarita Bajaj
ADAshok Kumar Das
Ashok Kumar Das
AZAh Zargar
Ah Zargar

3 April 2026 in Cancer Letters
Verified
Journal Article
Open access
RCRonghao Chen
Ronghao Chen
SRSwetha Rajasekaran
Swetha Rajasekaran
XXXuanxuan Xing
Xuanxuan Xing
QZQian Zhang
Qian Zhang
SSSydney M. Steele
Sydney M. Steele
WMWayne Miles
Wayne Miles
PD-L1 drives T cell exhaustion and tumor immune evasion and is transcriptionally induced by immune cell-derived IFN-γ. Here, we find that the RNA-binding protein PUM1 recognizes a conserved 3'UTR motif in PD-L1 and is itself induced by IFN-γ. In PUM1-deficient cells, PD-L1 fails to accumulate with IFN-γ stimulation, revealing that IFN-γ also regulates PD-L1 through PUM1-mediated post-transcriptional mechanisms. Mechanistically, we identify HNRNPA2B1 as a direct competitor of PUM1 for PD-L1 mRNA binding, thereby controlling RNA stability and protein expression. In syngeneic colon cancer models, PUM1 deficiency reduces PD-L1, slows tumor growth, and enhances CD8+ T cell infiltration, whereas HNRNPA2B1 depletion restores PD-L1 and suppresses CD8+ T cells. Mutation of the endogenous PUM1-binding site similarly reduces PD-L1 and restrains tumor progression. Consistently, single-cell analysis of colorectal tumors shows PUM1 positively correlates with PD-L1 and inversely with CD8+ T cell infiltration. Together, our study defines a novel IFN-γ-responsive post-transcriptional regulation that controls PD-L1 expression and tumor immune suppression.

27 May 2022 in Diagnostics
Verified
Journal Article
Open access
PDF file
VKVikas Kumar
Vikas Kumar
MLMoien Rasheed Lone
Moien Rasheed Lone
AKANURAG KUMAR
ANURAG KUMAR
VVVinnyfred Vincent
Vinnyfred Vincent
HTHimani Thakkar
Himani Thakkar
SCShyam Chauhan
Shyam Chauhan
The heterogeneous nuclear ribonucleoprotein D (hnRNPD) serves as a prognostic marker for oral squamous cell carcinoma (OSCC). We evaluated the diagnostic potential of hnRNPD to differentiate between OSCC and normal mucosa. Immunohistochemistry for hnRNPD and a routinely used diagnostic marker deltaNp63 (p40) was performed in 32 normal mucosae and 46 OSCC specimens. Subsequently, receiver-operating characteristic analysis was performed to evaluate the diagnostic potential of hnRNPD in comparison to that of p40. Immunostaining for p40 and hnRNPD was observed in 39 (84.78%) and 38 (82.60%) cases, respectively, in OSCC specimens. The poorly differentiated squamous cell carcinoma displayed 100% (eight cases) immunoreactivity for hnRNPD as compared to 87.5% (seven cases) for p40. Nuclear staining of p40 and hnRNPD was observed in all OSCC specimens. p40 staining was restricted to basal cells, whereas both basal and para-basal cells displayed hnRNPD staining in OSCC specimens. Areas under the curve for p40 and hnRNPD were 0.86 and 0.87, respectively. p40 and hnRNPD showed equal sensitivities (80.95%). However, hnRNPD displayed marginally higher (88.23%) specificity for tumor cells as compared to that of p40 (85.29%). Conclusion: In addition to being a well-established prognostic marker, hnRNPD can serve as a diagnostic marker for OSCC.

22 September 2026 in Next Nanotechnology
Verified
Journal Article
Open access
DGDipanjan Ghosh
Dipanjan Ghosh
PGPriya Gupta
Priya Gupta
VKVikas Kumar
Vikas Kumar
AKANURAG KUMAR
ANURAG KUMAR
AAAshok Kumar Ahirwar
Ashok Kumar Ahirwar
ATAbhimanyu Thakur
Abhimanyu Thakur

5 January 2025 in bioRxiv
Verified
Preprint
Open access
PDF file
VKVikas Kumar
Vikas Kumar
AMAnjani Mittal
Anjani Mittal
AKAnurag Kumar
Anurag Kumar
MLMoien Rasheed Lone
Moien Rasheed Lone
VYVandana Yadav
Vandana Yadav
SCShyam Chauhan
Shyam Chauhan
Summary: Heterogeneous Ribonucleoprotein D (hnRNPD), an RNA binding protein transcriptionally upregulated by NF-κB transcription factor, is associated with poor outcome of Oral Squamous Cell Carcinoma (OSCC). However, the role of hnRNPD in OSCC remains elusive. This study reveals that hnRNPD positively affects the proliferation, migration, invasion, and survival of OSCC cells. Transcriptome profiling in hnRNPD knockout cells identified significant upregulation of PTEN and inhibition of the PI3K/AKT/mTOR axis. HnRNPD mediates the destabilization of PTEN mRNA by binding to the class II AU-Rich Element (ARE) in 3’UTR of PTEN. The expression of hnRNPD and PTEN are strongly negatively correlated in OSCC tissue specimens, further corroborating hnRNPD-mediated PTEN destabilization. The hnRNPD knockout inhibited autophagy, evident by an accumulation of autophagic vesicles and decreased autophagic flux. Mechanistically, the hnRNPD knockout reduced the expression of NF-κB, eventually downregulating its transcriptional target LC3b, a key mediator of autophagy. SA-β-Galactosidase staining in hnRNPD KO cells conclusively demonstrated the onset of cellular senescence. The present study demonstrates hnRNPD-driven positive modulation of autophagy via NF-κB, independent of the PI3K/AKT/mTOR axis, highlighting it as a novel therapeutic target for treating oral cancer. Graphical Highlights: HnRNPD mediates oral cancer cell proliferation, migration, invasion, and survival. HnRNPD acts as a novel regulator of the PI3K/AKT/mTOR axis by destabilization of PTEN. NF-κB/RelA downregulated on knockout of HNRNPD, inhibiting autophagy through downregulating its transcriptional target LCB-II. HnRNPD mediates cellular senescence in oral cancer cells.